Get all your news in one place.

100's of premium titles.
One app.

Get all your news in one place.

100's of premium titles. One news app.

MYSTERIOUS: Insmed | Mind Blowing Facts

Insmed CEO Defends BRINSUPRI Launch as Sales Surge, TPIP Pipeline Gains Focus

Insmed (NASDAQ:INSM) Chair and CEO Will Lewis said the company remains confident in the launch trajectory of BRINSUPRI, despite investor concerns over discontinuation rates that followed the company’s latest update. Speaking at a Bank of America healthcare conference, Lewis said the company intended

This ‘Strong Buy’ Stock Is Trading at New 20-Year Highs

This ‘Strong Buy’ Stock Is Trading at New 20-Year Highs

Insmed (INSM) is a biopharmaceutical company with strong momentum. Shares are trading at new 20-year highs. INSM has surged 128% over the past year. Analysts expect robust revenue and earnings growth, but opinions are mixed, with some cautioning the stock is overvalued. Today’s Featured Stock Valued at $34.3 billion, Insmed...

6 Stocks Goldman Sachs Says Are Poised For Potential Acquisition In Next 12 Months — Including A Huge 200% Winner

6 Stocks Goldman Sachs Says Are Poised For Potential Acquisition In Next 12 Months — Including A Huge 200% Winner

Goldman Sachs has highlighted six stocks that have a high probability of being acquisition targets in the next year.

From analysis to the latest developments in health,
read the most diverse news in one place.

inkl

Lung Disease-Focused Insmed 'Must-Own' Name For Investors

William Blair initiated coverage on Insmed Incorporated (NASDAQ:INSM), citing that the clinical and commercial execution of its drugs can significantly increase Insmed's valuation.

This ‘Strong Buy’ Pharma Stock Is Surging to New Highs

Insmed (INSM) shows strong technical momentum, hitting a new 52-week high on Aug. 18. INSM has a 100% “Buy” opinion from Barchart with impressive recent gains. Revenue is projected to grow nearly 29% this year and 126% next year, with earnings growth expected to accelerate in 2026. Wall Street analysts...

Cramer Says Tesla Dominates While Ouster Is 'Too Speculative'

In a market increasingly defined by volatility and uncertainty, investors are grappling with a mix of opportunities and risks. The recent turmoil in the tech sector, particularly among companies heavily reliant on artificial intelligence, has raised questions about sustainability and profitability.

Russell Rebalance: 3 Stocks Ready to Move Higher

The Russell reconstitution is underway; here are three stocks that are garnering interest as stocks that could move up to the Russell 1000

inkl

Read news from The Economist, FT, and more,
with one subscription

Insmed's Return On Capital Employed Overview

Insmed's Return On Capital Employed Overview

According to data from Benzinga Pro, during Q1, Insmed's (NASDAQ:INSM) reported sales totaled $53.11 million. Despite a 16.25% increase in earnings, the company posted a loss of $94.62 million.

Insmed: Q1 Earnings Insights

Insmed: Q1 Earnings Insights

Insmed (NASDAQ:INSM) reported its Q1 earnings results on Thursday, May 5, 2022 at 07:30 AM. Here's what investors need to know about the announcement.

How To Attend Insmed Q1 2022 Earnings Conference Call

How To Attend Insmed Q1 2022 Earnings Conference Call

Insmed (NASDAQ:INSM) will host a conference call at 08:30 AM ET on May 5, 2022, to discuss Q1 2022 earnings results. How to Attend Insmed (INSM) Conference Call Follow this link to access the live webcast.

Benzinga's Top Ratings Upgrades, Downgrades For April 27, 2022

Benzinga's Top Ratings Upgrades, Downgrades For April 27, 2022

Insmed's Return On Capital Employed Insights

Insmed's Return On Capital Employed Insights

Insmed (NASDAQ:INSM) brought in sales totaling $56.12 million during Q4 according to data provided by Benzinga Pro. However, earnings decreased 0.23%, resulting in a loss of $112.98 million.

Insmed: Q4 Earnings Insights

Insmed: Q4 Earnings Insights

Insmed (NASDAQ:INSM) reported its Q4 earnings results on Thursday, February 17, 2022 at 07:30 AM. Here's what investors need to know about the announcement.

1

People

Jim Van Meerten

From analysis to the latest developments in health,
read the most diverse news in one place.

inkl

Organisations

Bank of America

B of A Securities

JetBlue Airways

Benzinga Edge Stock Rankings

inkl

Read news from The Economist, FT, and more,
with one subscription

Topics

Places

381,679 stories

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.

Download on the AppStore

Get it on Google Play